Maravai LifeSciences/$MRVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Maravai LifeSciences
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Ticker
$MRVI
Sector
Primary listing
Employees
560
Headquarters
Website
MRVI Metrics
BasicAdvanced
$346M
-
-$1.35
0.28
-
Price and volume
Market cap
$346M
Beta
0.28
52-week high
$9.41
52-week low
$1.67
Average daily volume
1.6M
Financial strength
Current ratio
5.163
Quick ratio
4.274
Long term debt to equity
76.25
Total debt to equity
79.293
Interest coverage (TTM)
-2.87%
Profitability
EBITDA (TTM)
-60.204
Gross margin (TTM)
30.53%
Net profit margin (TTM)
-87.57%
Operating margin (TTM)
-50.21%
Effective tax rate (TTM)
1.11%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-5.89%
Return on equity (TTM)
-54.84%
Valuation
Price to revenue (TTM)
1.552
Price to book
1.3
Price to tangible book (TTM)
-6.1
Price to free cash flow (TTM)
-7.549
Free cash flow yield (TTM)
-13.25%
Free cash flow per share (TTM)
-0.317
Growth
Revenue change (TTM)
-19.95%
Earnings per share change (TTM)
33.60%
3-year revenue growth (CAGR)
-37.95%
3-year earnings per share growth (CAGR)
-10.95%
What the Analysts think about MRVI
Analyst ratings (Buy, Hold, Sell) for Maravai LifeSciences stock.
Bulls say / Bears say
Repligen approached Maravai with a $2.5 billion acquisition offer in August 2024, driving a 20% stock rally and highlighting strategic value recognition and potential takeover premium for shareholders (Reuters)
In January 2025, Maravai acquired intellectual property and assets from Molecular Assemblies, strengthening TriLink’s enzymatic DNA synthesis capabilities and expanding its mRNA and oligonucleotide manufacturing platform for next-generation therapies (GenomeWeb)
Management reaffirmed full-year 2025 revenue guidance of $185 million to $205 million in March 2025, signaling confidence in its return-to-growth strategy amid macroeconomic headwinds (Reuters)
Quarterly revenue in Q4 2024 came in at $56.6 million, slightly below the $56.67 million consensus estimate, while full-year 2024 revenue of $259 million marked a 10.3% year-over-year decline, highlighting persistent demand weakness in core segments (Reuters)
Adjusted loss per share of $0.06 in Q4 2024 was wider than the $0.04 expected, and analysts cited a $7 million shortfall in EBITDA, while GAAP net loss for 2024 widened to $260 million, underscoring deepening profitability challenges (Reuters)
Shares fell nearly 6% on March 19, 2025, after management disclosed material weaknesses in internal controls over revenue recognition and goodwill impairment during its earnings call, adding to a 21% drop when Q4 2024 results were delayed and underscoring governance and reporting risks (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 10 Aug 2025.
MRVI Financial Performance
Revenues and expenses
MRVI Earnings Performance
Company profitability
MRVI News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation
Accesswire·2 months ago
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation
Accesswire·2 months ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Shareholders to Connect
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Maravai LifeSciences stock?
Maravai LifeSciences (MRVI) has a market cap of $346M as of August 22, 2025.
What is the P/E ratio for Maravai LifeSciences stock?
The price to earnings (P/E) ratio for Maravai LifeSciences (MRVI) stock is 0 as of August 22, 2025.
Does Maravai LifeSciences stock pay dividends?
No, Maravai LifeSciences (MRVI) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Maravai LifeSciences dividend payment date?
Maravai LifeSciences (MRVI) stock does not pay dividends to its shareholders.
What is the beta indicator for Maravai LifeSciences?
Maravai LifeSciences (MRVI) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.